Atezolizumab and bevacizumab in combination is in clinical development for treating adults with high risk
of hepatocellular carcinoma (HCC) coming back (recurring), after complete surgical removal
(resection/ablation) of the affected tissue. HCC is the most common type of primary liver cancer, which
affects men more than women, and is more likely to develop the older a person gets.
Atezolizumab with bevacizumab for patients with resected or ablated hepatocellular carcinoma who are at high risk for disease recurrence
![featured image](https://www.io.nihr.ac.uk/wp-content/uploads/2022/01/Patients-Public_Motifs_Conduction-broadcasting_RGB-scaled_edit1233.jpg)
Atezolizumab and bevacizumab in combination is in clinical development for treating adults with high risk of hepatocellular carcinoma (HCC) coming back (recurring), after complete surgical removal (resection/ablation) of the affected tissue.
Indications:
Hepatocellular carcinoma (HCC)
Therapeutic Areas:
Gastrointestinal Cancer
Year:
2022